Jilin Jian Yisheng Pharmaceutical Co., Ltd. (002566.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 7.03

From 52W high−25.52%

Volume5.50M

Market capCNY 2.23B

P/E (TTM)76.9x

P/S (TTM)3.5x

Div yield1.15%

Key dataSep 18, 2026

Open

CNY 7.03

From 52W high

−25.52%

Volume

5.50M

Market cap

CNY 2.23B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

37.3x

P/E (TTM)

76.9x

RSI (14)

50.7

MomentumView details →

1D Return

−0.74%

YTD Return

−8.78%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

76.9x

EV/EBITDA

37.3x

EV/Sales

4.0x

P/S (TTM)

3.5x

P/B (TTM)

1.0x

ProfitabilityView details →

Gross Margin

74.04%

Net Margin

5.05%

EBITDA Margin

10.69%

ROE (TTM)

1.48%

ROA (TTM)

1.11%

Asset Turnover

0.22x

GrowthView details →

Revenue YoY

+5.17%

EPS YoY

−22.44%

FCF YoY

+264.39%

Revenue CAGR 3Y

−8.29%

EPS CAGR 3Y

−29.60%

EBITDA YoY

—

MomentumView details →

1D Return

−0.74%

YTD Return

−8.78%

1Y Return

−11.00%

RSI (14)

50.7

vs 50D SMA

+3.31%

vs 200D SMA

−7.13%

Capital & dividendView details →

Debt/Equity

0.21x

Current Ratio

5.86x

Quick Ratio

2.10x

Div Yield

1.15%

Div Rate

CNY 0.08

Div Growth 1Y

−20.00%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

659.66M

Net Income (TTM)

33.28M

Op. CF (TTM)

108.30M

Latest newsMore news →

Yisheng Pharmaceutical announced its first-half 2026 results with revenue of 338 million yuan, up 3.25% year-on-year, and net profit attributable to shareholders of 26.83 million yuan, up 42.99%.27d ago

Yisheng Pharmaceutical initiated a product recall and launched a comprehensive self-inspection and rectification campaign across its production system.76d ago

Similar companies

博菲电气001255.SZ 裕兴股份300305.SZ 佳隆股份002495.SZ 智迪科技301503.SZ 恩威医药301331.SZ 双乐股份301036.SZ Find similar companies →

Latest newsMore news →

Yisheng Pharmaceutical announced its first-half 2026 results with revenue of 338 million yuan, up 3.25% year-on-year, and net profit attributable to shareholders of 26.83 million yuan, up 42.99%.27d ago Yisheng Pharmaceutical initiated a product recall and launched a comprehensive self-inspection and rectification campaign across its production system.76d ago Yisheng Pharmaceutical received a notice from Jilin Provincial Drug Administration on July 1, 2026, ordering the suspension of production and sales of Shengmai Injection and Bujin Tablets due to serious defects and safety hazards found during an inspection from June 26 to 28, 2026.78d ago